Logo image of NTRA

NATERA INC (NTRA) Stock Fundamental Analysis

NASDAQ:NTRA - Nasdaq - US6323071042 - Common Stock - Currency: USD

151.95  +10.87 (+7.7%)

After market: 151.95 0 (0%)

Fundamental Rating

4

Taking everything into account, NTRA scores 4 out of 10 in our fundamental rating. NTRA was compared to 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NTRA as it has an excellent financial health rating, but there are worries on the profitability. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year NTRA has reported negative net income.
NTRA had a positive operating cash flow in the past year.
NTRA had negative earnings in each of the past 5 years.
NTRA had negative operating cash flow in 4 of the past 5 years.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

The Return On Assets of NTRA (-10.95%) is better than 83.12% of its industry peers.
NTRA has a better Return On Equity (-15.31%) than 87.11% of its industry peers.
Industry RankSector Rank
ROA -10.95%
ROE -15.31%
ROIC N/A
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Gross Margin of NTRA (61.79%) is better than 79.31% of its industry peers.
In the last couple of years the Gross Margin of NTRA has grown nicely.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

7

2. Health

2.1 Basic Checks

NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTRA has more shares outstanding
The number of shares outstanding for NTRA has been increased compared to 5 years ago.
NTRA has a better debt/assets ratio than last year.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

NTRA has an Altman-Z score of 24.49. This indicates that NTRA is financially healthy and has little risk of bankruptcy at the moment.
NTRA has a better Altman-Z score (24.49) than 94.74% of its industry peers.
The Debt to FCF ratio of NTRA is 0.94, which is an excellent value as it means it would take NTRA, only 0.94 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.94, NTRA belongs to the best of the industry, outperforming 95.28% of the companies in the same industry.
A Debt/Equity ratio of 0.06 indicates that NTRA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.06, NTRA is doing worse than 63.16% of the companies in the same industry.
Although NTRA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.94
Altman-Z 24.49
ROIC/WACCN/A
WACC11.1%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

NTRA has a Current Ratio of 3.87. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.87, NTRA perfoms like the industry average, outperforming 45.19% of the companies in the same industry.
NTRA has a Quick Ratio of 3.74. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.74, NTRA is in line with its industry, outperforming 45.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.87
Quick Ratio 3.74
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

NTRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.04%, which is quite impressive.
NTRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.75%.
NTRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.20% yearly.
EPS 1Y (TTM)22.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.67%
Revenue 1Y (TTM)56.75%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%32.24%

3.2 Future

The Earnings Per Share is expected to grow by 28.79% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.78% on average over the next years. This is quite good.
EPS Next Y-46.63%
EPS Next 2Y14.74%
EPS Next 3Y28.2%
EPS Next 5Y28.79%
Revenue Next Year20.47%
Revenue Next 2Y18.3%
Revenue Next 3Y17.69%
Revenue Next 5Y14.78%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of NTRA indicates a rather cheap valuation: NTRA is cheaper than 90.93% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 243.55
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as NTRA's earnings are expected to grow with 28.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.74%
EPS Next 3Y28.2%

More info and screens

0

5. Dividend

5.1 Amount

NTRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NATERA INC

NASDAQ:NTRA (8/8/2025, 8:00:02 PM)

After market: 151.95 0 (0%)

151.95

+10.87 (+7.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners93.56%
Inst Owner Change0.07%
Ins Owners3.15%
Ins Owner Change-2.61%
Market Cap20.75B
Analysts85
Price Target196.47 (29.3%)
Short Float %2.82%
Short Ratio2.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.14%
Min EPS beat(2)-2.77%
Max EPS beat(2)23.06%
EPS beat(4)3
Avg EPS beat(4)33.31%
Min EPS beat(4)-2.77%
Max EPS beat(4)57.31%
EPS beat(8)7
Avg EPS beat(8)23.1%
EPS beat(12)10
Avg EPS beat(12)16.88%
EPS beat(16)11
Avg EPS beat(16)9.64%
Revenue beat(2)2
Avg Revenue beat(2)9.58%
Min Revenue beat(2)8.92%
Max Revenue beat(2)10.25%
Revenue beat(4)4
Avg Revenue beat(4)14.15%
Min Revenue beat(4)8.92%
Max Revenue beat(4)19.28%
Revenue beat(8)8
Avg Revenue beat(8)10.59%
Revenue beat(12)10
Avg Revenue beat(12)7.32%
Revenue beat(16)14
Avg Revenue beat(16)6.54%
PT rev (1m)-3.81%
PT rev (3m)-1.75%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)-8.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.9%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)2.61%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)3.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.33
P/FCF 243.55
P/OCF 135.51
P/B 16.74
P/tB 16.74
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)0.62
FCFY0.41%
OCF(TTM)1.12
OCFY0.74%
SpS13.41
BVpS9.08
TBVpS9.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.95%
ROE -15.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.79%
FCFM 4.65%
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
F-Score6
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.94
Debt/EBITDA N/A
Cap/Depr 204.95%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.87
Quick Ratio 3.74
Altman-Z 24.49
F-Score6
WACC11.1%
ROIC/WACCN/A
Cap/Depr(3y)232.23%
Cap/Depr(5y)273.02%
Cap/Sales(3y)4.66%
Cap/Sales(5y)5.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.67%
EPS Next Y-46.63%
EPS Next 2Y14.74%
EPS Next 3Y28.2%
EPS Next 5Y28.79%
Revenue 1Y (TTM)56.75%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%32.24%
Revenue Next Year20.47%
Revenue Next 2Y18.3%
Revenue Next 3Y17.69%
Revenue Next 5Y14.78%
EBIT growth 1Y40.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.42%
EBIT Next 3Y37.85%
EBIT Next 5Y33.74%
FCF growth 1Y120.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.82%
OCF growth 3YN/A
OCF growth 5YN/A